Creating new peptides to fight drug-resistant bacteria
Development of Broad-Spectrum Cyclic Amphiphilic Peptides against Multidrug-Resistant Bacteria
This study is looking at new types of antimicrobial peptides that could help fight tough bacteria that don't respond to regular antibiotics, aiming to create safer and more effective treatments for infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ajk Biopharmaceutical LLC NIH-funded |
| Lab location | 1 site (Mission Viejo, United States) |
| Project ID | NIH-10685928 on NIH RePORTER |
What this research studies
This research focuses on developing innovative cyclic antimicrobial peptides that can effectively combat multidrug-resistant bacteria, which pose a significant threat to public health. The approach involves synthesizing unique peptides that incorporate both natural and synthetic amino acids to enhance their antibacterial properties. Through laboratory tests, the effectiveness of these peptides against various harmful bacteria, including Klebsiella pneumoniae and Staphylococcus aureus, will be evaluated. The goal is to create new treatments that are less toxic and more effective than current antibiotics.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are suffering from infections caused by multidrug-resistant bacteria.
Not a fit: Patients with infections caused by bacteria that are not multidrug-resistant may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new antimicrobial treatments that effectively target and eliminate drug-resistant infections.
How similar studies have performed: Previous research has shown promise in developing antimicrobial peptides, indicating potential for success in this novel approach.
Where this research is happening
Mission Viejo, United States
- Ajk Biopharmaceutical LLC — Mission Viejo, United States (Active)
Researchers
- Principal investigator: Kazeminy, Assad — Ajk Biopharmaceutical LLC
- Study coordinator: Kazeminy, Assad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.